← Leaderboards
Reginald F Frye
University Of Pittsburgh At Pittsburgh
$1,669,839
Attributed
$1,669,839
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $287.5K · FY2010–11$500K$375K$250K$125K$0
'10
'11
Funding mix
By agency
NIH$1,669,839 · 7
By mechanism
R01$955,118 · 1
R21$571,507 · 1
M01$143,214 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- William E Klunk$26,129,826
- Oscar L. Lopez$26,660,804
- Robert A Branch$5,498,174
- Angus W Thomson$32,884,902
- Fadi G. Lakkis$19,632,585
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectDrug MetabolismClinical ResearchCytochrome P450Enzyme ActivityDrug InteractionsMidazolamPharmacokineticsGastrointestinal PharmacologyLiver PharmacologyMicroorganism Disease ChemotherapyImmunotherapyHuman Therapy EvaluationInterferonsHepatitis CPhenotypeLiver Disorder ChemotherapyPatient Oriented ResearchAnticonvulsantsEnzyme Induction /RepressionCaffeineAlternative MedicineDepressionAngiosperms
Grant awards (16)
Herb-Drug Glucuronidation Interactions$283,982
R21 · FY2011 · AT · contact PI
Herb-Drug Glucuronidation Interactions$287,525
R21 · FY2010 · AT · contact PI
Mechanisms of Atypical Kinetics and Interactions In Vivo Activ. Naproxen Demethn$57,998
M01 · FY2004 · RR
Effect of St. John's Wort on Pharmacokinetics$54,945
M01 · FY2004 · RR
Effect CYP2C8 Inhibition Trimethoprim on Rosiglitazone$30,271
M01 · FY2004 · RR
St. John's Wort and CYP3A Metabolism in Men &Women$290,000
R01 · FY2003 · MH
St. John's Wort and CYP3A Metabolism in Men &Women$335,974
R01 · FY2002 · MH
PHENOTYPING HEPATIC/ INTESTINAL CYP3A ACTIVITY W/ MIDAZO$0
M01 · FY2002 · RR
CHRONIC INTERFERON THERAPY IN HEPATITIS C ENZYME ACTIVIT$0
M01 · FY2002 · RR
CHRONIC INTERFERON THERAPY IN HEPATITIS C ENZYME ACTIVIT$0
M01 · FY2002 · RR
PHENOTYPING HEPATIC/ INTESTINAL CYP3A ACTIVITY W/ MIDAZO$0
M01 · FY2002 · RR
St. John's Wort and CYP3A Metabolism in Men &Women$329,144
R01 · FY2001 · MH
PHENOTYPING HEPATIC/ INTESTINAL CYP3A ACTIVITY W/ MIDAZO$0
M01 · FY2001 · RR
CHRONIC INTERFERON THERAPY IN HEPATITIS C ENZYME ACTIVIT$0
M01 · FY2001 · RR
CHRONIC INTERFERON THERAPY IN HEPATITIS C ENZYME ACTIVIT$0
M01 · FY2000 · RR
PHENOTYPING HEPATIC/ INTESTINAL CYP3A ACTIVITY W/ MIDAZO$0
M01 · FY2000 · RR